Take­da strikes a com­bo I/O dis­cov­ery pact with Shat­tuck Labs; Fac­ing FDA re­jec­tion, Egalet slash­es staff

⇨ Take­da’s Cam­bridge, MA-based on­col­o­gy group has struck a dis­cov­ery deal with Austin-based Shat­tuck Labs. The deal cen­ters on a com­bo im­muno-on­col­o­gy ap­proach to drug de­vel­op­ment, match­ing a check­point strat­e­gy with whip­ping up a T cell at­tack. Take­da will of­fer Shat­tuck un­spec­i­fied re­search sup­port in ex­change for con­trol of two pre-clin­i­cal and four dis­cov­ery stage can­cer pro­grams.

⇨ A few weeks af­ter get­ting a com­plete re­sponse let­ter from the FDA for its pri­or ap­proval sup­ple­ment of oxy al­ter­na­tive Ox­ay­do, the Wayne, PA-based Egalet $EGLT has be­gun cut­ting staff. In a re­lease the com­pa­ny said it would lay off 40% of its non-sales staff. The CRL proved a nasty set­back for the biotech’s stock.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER